BRIEF—BridgeBio buys ultra-rare disease candidate from Alexion

Californian biotech startup BridgeBio Pharma has inked a deal with Alexion Pharmaceuticals to acquire cyclic pyranopterin monophosphate, known as ALXN1101, a candidate treatment for the an ultra-rare disease caused by molybdenum cofactor deficiency (MoCD) Type A.

The firm will also launch a new subsidiary, Origin Biosciences, with sufficient capital to support full development of ALXN1101.

Alexion is due to receive payments upon the realization of development and sales milestones. Financial details were not disclosed.